# IBMSol

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ibmsol

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.ibmsol.co.kr/
- Latest round: Seed (Sep 30, 2021)
- Investors on record: 2

## About

Based in South Korea, IBMSol develops innovative bio-medical solutions, focusing on advanced medical devices and therapies to enhance treatment efficacy and patient care.IBMSol, founded in 2020 and headquartered in Seoul, South Korea, specializes in bio-medical innovations. The company's inception marked its commitment to developing sophisticated medical technologies. The founder, whose background is not specified, has successfully led IBMSol through its initial operational phase, culminating in a total of 1 deal by September 30, 2021.IBMSol specializes in innovative bio-medical solutions, focusing on the development and commercialization of advanced medical devices and therapies. Their core product offerings include a non-invasive cancer treatment technology based on bio-plasma, ultrasonic probe sterilizers, and infection management systems, along with targeted drug development for rare diseases. These products are designed to improve patient outcomes by providing effective treatment options while minimizing complications associated with traditional methods. The company's technology aims to address critical healthcare challenges, particularly in oncology and infectious disease management. IBMSol primarily serves hospitals, clinics, and healthcare providers across South Korea and is looking to expand its reach into other Asian markets.IBMSol operates with a revenue model that encompasses B2B transactions, primarily through direct sales to healthcare institutions and partnerships with medical distributors. The company generates income through the sale of its flagship products, including the bio-plasma based cancer treatment system and sterilizers, which are essential tools for modern medical facilities. Revenue streams are structured around one-time purchases, with potential for recurring sales as healthcare providers replenish inventory of consumable supplies or upgrade systems. This transactional framework supports a robust relationship with clients who benefit from the advanced technologies that enhance their medical offerings. Each product is positioned as a premium solution within the healthcare market, reflecting the company's commitment to quality and innovation.IBMSol plans to launch several new products designed to advance its medical technology offerings within the next year. The company is also targeting expansion into Southeast Asian markets by 2023, focusing on regions that demonstrate a growing demand for modern healthcare solutions. The funding raised from the most recent deal on September 30, 2021, will support these initiatives, enabling IBMSol to enhance its product development capabilities and facilitate market entry.

## Funding rounds

- Seed, Sep 30, 2021 — Coolidge Corner Investment, Venture Box

## Investors

- Coolidge Corner Investment (https://capitalatlas.ai/funds/coolidge-corner-investment) — Seed
- Venture Box — Seed